argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
- None.
- None.
The advancement of efgartigimod into Phase 3 for primary Sjogren's disease represents a significant milestone in argenx's clinical development pipeline. The progression is based on a comprehensive analysis of the Phase 2 RHO study, which indicates a favorable safety profile and efficacy across multiple clinical endpoints. The impact of these findings is substantial due to the lack of approved therapies targeting the underlying mechanisms of Sjogren's disease, a condition that predominantly affects women and is characterized by its diverse and often misdiagnosed symptoms.
From a medical research perspective, the utilization of the Composite of Relevant Endpoints for Sjogren's Syndrome (CRESS) and the EULAR Sjogren's Syndrome Activity Index (ESSDAI) in the RHO study design is noteworthy. These endpoints are important for assessing systemic disease activity and patient-reported outcomes, which are central to evaluating the potential benefits of new therapies in autoimmune diseases. The positive correlation between these endpoints and biomarker data enhances the credibility of the results and supports the therapeutic hypothesis of efgartigimod's mechanism of action.
As the study moves into Phase 3, the focus will be on confirming these findings in a larger patient population and further establishing the drug's safety and efficacy profile. The long-term implications for stakeholders include the potential for efgartigimod to become a first-in-class treatment for Sjogren's disease, addressing a significant unmet medical need and potentially improving the quality of life for patients suffering from this chronic condition.
The transition of efgartigimod into Phase 3 trials holds financial implications for argenx SE and its investors. The positive outcomes from the Phase 2 RHO study suggest a strong potential for the drug to meet an unmet need in the market for primary Sjogren's disease treatments. This progression could positively influence investor sentiment and the valuation of argenx, as the market often responds favorably to advancements in drug development that have the potential to address untapped markets.
Investors should consider the costs associated with Phase 3 clinical trials, which are typically more substantial than earlier phases due to the larger scale and longer duration. However, the investment in these trials could be justified by the potential market size for Sjogren's disease treatments. The financial success of efgartigimod will depend on several factors, including the final clinical trial results, the drug's safety profile, market acceptance and the competitive landscape. If approved, efgartigimod could provide a new revenue stream for argenx, enhancing its portfolio and market position in the immunology sector.
It is also important to note that the biotech industry is subject to high volatility based on clinical trial outcomes. Therefore, while the advancement to Phase 3 is promising, it is essential for stakeholders to remain aware of the inherent risks and uncertainties that accompany drug development.
The advancement of efgartigimod for primary Sjogren's disease into Phase 3 trials is indicative of the drug's potential to capture a significant share of the autoimmune disease treatment market. The current landscape for Sjogren's disease is characterized by a lack of targeted therapies, which presents a considerable opportunity for argenx. The company's strategic focus on immunology and severe autoimmune diseases aligns with the growing demand for innovative treatments in this area.
Market analysis suggests that if efgartigimod is successful in Phase 3 and gains regulatory approval, it could disrupt the current treatment paradigm for Sjogren's disease. The drug's ability to address multiple efficacy scales and its favorable safety profile could make it a preferred option for healthcare providers and patients. Additionally, the focus on biomarker measures in the RHO study could facilitate personalized medicine approaches, further differentiating efgartigimod in the market.
Long-term market success will hinge on strategic pricing, effective marketing and the establishment of strong distribution channels. Payer acceptance and reimbursement will also play critical roles in the commercial viability of the drug. As the healthcare market continues to evolve, with an increasing emphasis on outcomes-based medicine and patient-centric care, treatments like efgartigimod that demonstrate clear clinical benefits and align with these trends are well-positioned for success.
RHO study supports proof-of-concept in primary Sjogren’s disease
Decision informed by favorable safety profile and consistency across efficacy and biomarker measures
March 27, 2024, 7:00 AM CET
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its plan to continue the development of efgartigimod to Phase 3 in adults with primary Sjogren’s disease (SjD), following the analysis of topline data from the Phase 2 RHO study. Detailed results will be presented at a future medical meeting.
“We are excited to be advancing efgartigimod’s development in Sjogren’s disease based on the totality of the data generated from the RHO study,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. “Consistent with our indication selection strategy, we confirmed our IgG biology hypothesis with these data, and now have a demonstrated clinical effect across multiple efficacy scales to support proof-of-concept. Sjogren’s disease can be debilitating, predominantly affects women, and given its heterogeneous nature, is often misdiagnosed with its symptoms poorly understood. With no current approved therapies to treat the underlying disease, the unmet need is substantial, and we recognize the opportunity to advance a new potential alternative treatment to these patients.”
The decision to advance the clinical development of efgartigimod in SjD was supported by the safety, efficacy and biomarker results from the study. The observed safety and tolerability profile was consistent with other clinical trials. Efficacy assessments showed a treatment effect across multiple clinical endpoints, which were also consistent with biomarker data.
RHO Study Design
The Phase 2 RHO study was a randomized, double-blinded, placebo-controlled multicenter proof of concept study to evaluate the safety and efficacy of VYVGART in adults with SjD. In order to enter the study, patients needed to test positive for anti-Ro autoantibodies and maintain residual salivary flow. Thirty four patients were randomized 2:1 to receive either efgartigimod or placebo for up to 24 weeks. Multiple endpoints and biomarkers were evaluated in the signal-finding study, including the primary endpoint of CRESS (Composite of Relevant Endpoints for Sjogren’s Syndrome). Within CRESS there are five components spanning: systemic disease activity as measured by the ESSDAI (EULAR Sjogren’s Syndrome Activity Index), patient reported outcomes as measured by the ESSPRI (EULAR Sjogren’s Syndrome Patient Reported Index), tear and salivary gland function and serology. To be a CRESS responder, patients needed to demonstrate a clinically meaningful benefit in at least 3 of the 5 composite items. Additional datapoints were gathered including the clinESSDAI, STAR (Sjogren’s Tool for Assessing Response), biomarker data, and the change in lymphocytic infiltrate levels through parotid biopsies.
About Sjogren’s Disease
Sjogren’s Disease (SjD) is a chronic, slowly progressive inflammatory systemic autoimmune disease characterized by immune-mediated destruction of exocrine glands. SjD can be severely debilitating and have a negative impact on patient quality of life, with common symptoms reported as dry eyes and mouth, fatigue, joint point and impaired cognitive function. In addition, a substantial subset of patients suffer from extraglandular systemic disease. While the presence of anti-Ro and anti-LA IgG autoantibodies are considered a hallmark of disease, the underlying cause of SjD is believed to be multi-factorial, triggered by environmental factors, leading to auto-immunity and chronic inflammation. SjD predominantly impacts women with a 9:1 female:male incidence ratio. Given the heterogeneous nature of the disease, the treatment journey can be challenging with long delays and high rates of misdiagnosis. There are no FDA-approved treatments targeting the disease itself, leaving current treatments to focus primarily on individual symptom management.
About Efgartigimod
Efgartigimod is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process. Efgartigimod is being investigated in several autoimmune diseases known to be mediated by disease-causing IgG antibodies, including neuromuscular disorders, blood disorders, and skin blistering diseases, in both an intravenous and subcutaneous (SC) formulation. Efgartigimod is marketed as VYVGART® for the treatment of generalized myasthenia gravis in more than 30 regions globally and immune thrombocytopenia in Japan.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X (formerly known as Twitter), and Instagram.
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
Forward Looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “aims,” “committed,” “plan” or “potential” and include statements argenx makes concerning its plan to continue the development to Phase 3 of efgartigimod for adults with primary SjD; the potential impact of efgartigimod for SjD patients; the advancement of, and anticipated clinical developmentof efgartigimod’s development in primary SjD and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials, expectations regarding the inherent uncertainties associated with development of novel drug therapies, preclinical and clinical trial and product development activities and regulatory approval requirements, the acceptance of our products and product candidates by our patients as safe, effective and cost-effective, and the impact of governmental laws and regulations on our business. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
FAQ
What is argenx SE's plan following the Phase 2 RHO study results for efgartigimod in primary Sjogren’s disease?
What was the key factor in the decision to advance the clinical development of efgartigimod in Sjogren’s disease?
What were the primary endpoints evaluated in the Phase 2 RHO study for Sjogren’s disease?
How many patients were randomized in the Phase 2 RHO study for Sjogren’s disease?
What is the significance of the Phase 2 RHO study results for efgartigimod in Sjogren’s disease?
